- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05677022
Evaluation of the Interest of a Postural and Functional Analysis for the Follow-up of the Adapted Motor Activity of Patients Treated for Breast Cancer (APECS)
The goal of this clinical trial is to evaluate the acceptability by patients treated for breast cancer of an adapted motor activity program over a period of 15 months controlled by a postural and functional analysis..
Participant population/health conditions: patients with newly operated breast cancer who are candidates for an adapted physical activity program
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a prospective, longitudinal, single-center, open-label study of a population of newly operated breast cancer patients who were candidates for an adapted motor activity program.
All included patients will be followed for a period of 15 months. Participating physicians will have the opportunity to recruit their patients during the 24 months following the study's initiation. The study will be completed once the last included patient has a final evaluation. The total duration of the study is 39 months (24 months of recruitment and 15 months of follow-up).
Each patient will be assessed four times: at inclusion before initiation of cancer treatment, and at M3, M9 and M15. At each patient visit with the investigating physician, an assessment will be completed on the electronic CRF by the physician or by the site CRA under the responsibility of the investigating physician.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Cyril FOA, MD
- Phone Number: 33 04 91 17 14 83
- Email: foacyril@club-internet.fr
Study Contact Backup
- Name: Emilie BIALECKI, PHD
- Phone Number: 33 04 91 17 14 28
- Email: emilie.bialecki@outlook.fr
Study Locations
-
-
-
Marseille, France, 13009
- Clairval Hospital Center
-
Principal Investigator:
- Cyril FOA, MD
-
Contact:
- Emilie Bialecki, PHD
- Phone Number: 491171428
- Email: emilie.bialecki@outlook.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult woman, having given her consent to participate in the study,
- Patient with non-metastatic breast cancer,
- Cancer to be treated by surgery with or without adjuvant treatment (radiotherapy and/or chemotherapy).
Exclusion Criteria:
- Contraindication to the practice of a physical activity,
- Mental deficiency or any other reason that could hinder the understanding or the strict application of the protocol,
- Patient not affiliated to the French social security system,
- Patient under legal protection, guardianship or curatorship,
- Patient already included in another therapeutic study protocol aimed at evaluating the benefits of adapted physical activity.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Adapted motor activity
|
15-month adapted motor activity program based on a postural and functional analysis
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of compliance
Time Frame: Month 15
|
Patients will be considered compliant if they have attended more than 50% of the physical adaptation program sessions
|
Month 15
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of the functional impact of the disease
Time Frame: Month 3
|
The Primus is used to establish a score during the performance of a movement. The number and nature of the movements evaluated are independent from one patient to another, nevertheless 4 very precise movements will be carried out in all the patients included in this study: ironing, vacuuming, driving and the hand-grip. The tests performed on the same patient will be strictly identical from one examination to the next. A Primus score will be calculated for each gesture. A global score will be calculated for each patient. It corresponds to the total score obtained by the patient divided by the number of tests performed. For each test and for the global score, the score recorded at Day 0 will constitute the reference value. The evolution of the scores during the follow-up will be expressed as a percentage of variation in relation to this basal score. |
Month 3
|
Assessment of the functional impact of the disease
Time Frame: Month 9
|
The Primus is used to establish a score during the performance of a movement. The number and nature of the movements evaluated are independent from one patient to another, nevertheless 4 very precise movements will be carried out in all the patients included in this study: ironing, vacuuming, driving and the hand-grip. The tests performed on the same patient will be strictly identical from one examination to the next. A Primus score will be calculated for each gesture. A global score will be calculated for each patient. It corresponds to the total score obtained by the patient divided by the number of tests performed. For each test and for the global score, the score recorded at D0 will constitute the reference value. The evolution of the scores during the follow-up will be expressed as a percentage of variation in relation to this basal score. |
Month 9
|
Assessment of the functional impact of the disease
Time Frame: Month 15
|
The Primus is used to establish a score during the performance of a movement. The number and nature of the movements evaluated are independent from one patient to another, nevertheless 4 very precise movements will be carried out in all the patients included in this study: ironing, vacuuming, driving and the hand-grip. The tests performed on the same patient will be strictly identical from one examination to the next. A Primus score will be calculated for each gesture. A global score will be calculated for each patient. It corresponds to the total score obtained by the patient divided by the number of tests performed. For each test and for the global score, the score recorded at D0 will constitute the reference value. The evolution of the scores during the follow-up will be expressed as a percentage of variation in relation to this basal score. |
Month 15
|
Postural evaluation
Time Frame: Month 3
|
The postural evaluation will be carried out using a force platform with strain gauges as sensors, allowing to measure the moment of the vertical force exerted on the plate, and to locate the center of pressure of the feet and to record the variations on the antero-posterior and lateral axes. The dual-tray platform used in the study allows separate assessment of the forces exerted under each of the lower limbs. |
Month 3
|
Postural evaluation
Time Frame: Month 9
|
The postural evaluation will be carried out using a force platform with strain gauges as sensors, allowing to measure the moment of the vertical force exerted on the plate, and to locate the center of pressure of the feet and to record the variations on the antero-posterior and lateral axes. The dual-tray platform used in the study allows separate assessment of the forces exerted under each of the lower limbs. |
Month 9
|
Postural evaluation
Time Frame: Month 15
|
The postural evaluation will be carried out using a force platform with strain gauges as sensors, allowing to measure the moment of the vertical force exerted on the plate, and to locate the center of pressure of the feet and to record the variations on the antero-posterior and lateral axes. The dual-tray platform used in the study allows separate assessment of the forces exerted under each of the lower limbs. |
Month 15
|
Pain assessment
Time Frame: Month 3
|
Pain intensity will be assessed using a simple numerical scale (SNS) graduated from 0 (no pain) to 10 (worst pain imaginable).
|
Month 3
|
Pain assessment
Time Frame: Month 9
|
Pain intensity will be assessed using a simple numerical scale (SNS) graduated from 0 (no pain) to 10 (worst pain imaginable).
|
Month 9
|
Pain assessment
Time Frame: Month 15
|
Pain intensity will be assessed using a simple numerical scale (SNS) graduated from 0 (no pain) to 10 (worst pain imaginable).
|
Month 15
|
Functional and mobility assessment of the shoulder
Time Frame: Month 3
|
This evaluation will be carried out using the Constant questionnaire composed of 11 questions grouped into 4 items (pain, activities of daily living, mobility and power of the shoulder).
A global score ranging from 0 to 100 is obtained (almost no function to normal function).
|
Month 3
|
Functional and mobility assessment of the shoulder
Time Frame: Month 9
|
This evaluation will be carried out using the Constant questionnaire composed of 11 questions grouped into 4 items (pain, activities of daily living, mobility and power of the shoulder).
A global score ranging from 0 to 100 is obtained (almost no function to normal function).
|
Month 9
|
Functional and mobility assessment of the shoulder
Time Frame: Month 15
|
This evaluation will be carried out using the Constant questionnaire composed of 11 questions grouped into 4 items (pain, activities of daily living, mobility and power of the shoulder).
A global score ranging from 0 to 100 is obtained (almost no function to normal function).
|
Month 15
|
Assessment of the emotional impact of the disease
Time Frame: Month 3
|
The emotional impact of the disease will be more precisely evaluated by the HAD questionnaire, a screening tool for the most common manifestations of anxiety and depressive disorders to be completed by the patient.
The scale consists of 14 questions, with 7 items assessing anxiety and 7 items assessing depression.
A minimum score of 10 on one of the sub-scores was retained as a screening criterion for depressive or anxious manifestations.
|
Month 3
|
Assessment of the emotional impact of the disease
Time Frame: Month 9
|
The emotional impact of the disease will be more precisely evaluated by the HAD questionnaire, a screening tool for the most common manifestations of anxiety and depressive disorders to be completed by the patient.
The scale consists of 14 questions, with 7 items assessing anxiety and 7 items assessing depression.
A minimum score of 10 on one of the sub-scores was retained as a screening criterion for depressive or anxious manifestations.
|
Month 9
|
Assessment of the emotional impact of the disease
Time Frame: Month 15
|
The emotional impact of the disease will be more precisely evaluated by the HAD questionnaire, a screening tool for the most common manifestations of anxiety and depressive disorders to be completed by the patient.
The scale consists of 14 questions, with 7 items assessing anxiety and 7 items assessing depression.
A minimum score of 10 on one of the sub-scores was retained as a screening criterion for depressive or anxious manifestations.
|
Month 15
|
Assessment of the impact of the disease on quality of life
Time Frame: Month 3
|
Patients' quality of life will be assessed by completing the EORTC Core Quality of Life Questionnaire EORTC QLQ-C30 questionnaire with 30 questions
|
Month 3
|
Assessment of the impact of the disease on quality of life
Time Frame: Month 3
|
Patients' quality of life will be assessed by completing the EORTC Core Quality of Life Questionnaire EORTC QLQ-Br 23 module with 23 additional questions.
|
Month 3
|
Assessment of the impact of the disease on quality of life
Time Frame: Month 9
|
Patients' quality of life will be assessed by completing the EORTC Core Quality of Life Questionnaire EORTC QLQ-C30 questionnaire with 30 questions
|
Month 9
|
Assessment of the impact of the disease on quality of life
Time Frame: Month 9
|
Patients' quality of life will be assessed by completing the EORTC Core Quality of Life Questionnaire EORTC QLQ-Br 23 module with 23 additional questions.
|
Month 9
|
Assessment of the impact of the disease on quality of life
Time Frame: Month 15
|
Patients' quality of life will be assessed by completing the EORTC Core Quality of Life Questionnaire EORTC QLQ-C30 questionnaire with 30 questions.
|
Month 15
|
Assessment of the impact of the disease on quality of life
Time Frame: Month 15
|
Patients' quality of life will be assessed by completing the EORTC Core Quality of Life Questionnaire EORTC QLQ-Br 23 module with 23 additional questions.
|
Month 15
|
Assessment of sarcopenia
Time Frame: Month 15
|
Sarcopenia will be measured by impedancemetry.
The parameters collected will be in kilograms.
|
Month 15
|
Assessment of sarcopenia
Time Frame: Month 15
|
Sarcopenia will be measured by impedancemetry.
The parameters collected will be in percentage.
|
Month 15
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2021-A03091-40
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
Clinical Trials on Adapted motor activity
-
Assistance Publique Hopitaux De MarseilleNot yet recruiting
-
University Hospital, CaenNot yet recruitingChronic Pain | Multiple Myeloma | Adapted Physical Activity
-
Central Hospital, Nancy, FranceRecruiting
-
WepromRecruitingLymphoma | Myeloma | Autologous TransplantFrance
-
Centre Hospitalier Universitaire de NiceCompleted
-
Support and Education Technic CentreCompletedHeart Failure | Cardiovasculars Risk FactorsFrance, Cameroon
-
University of LausanneCompletedPostural ControlSwitzerland
-
Centre Hospitalier Universitaire de Saint EtienneCompleted
-
Centre Borelli UMR 9010Not yet recruitingAging | Fall | Motor Activity | Gait, Unsteady
-
WepromRecruitingDiffuse Large B Cell LymphomaFrance